GSK and Hansoh Pharma's B7-H3 ADC 'Risvutazug Rezetecan' Shows Improved Overall Survival in Phase 3 Trial for Small Cell Lung Cancer
First B7-H3 ADC to Demonstrate Overall Survival Benefit
GSK, a global pharmaceutical company, and Hansoh Pharma, a Chinese pharmaceutical company, are jointly developing risvutazug rezetecan (HS-20093), a B7-H3-targeted antibody-drug conjugate (ADC). In a Phase 3 clinical trial (ARTEMIS-008, NCT06498479) involving patients with small cell lung cancer (SCLC), risvutazug rezetecan demonstrated a statistically significant improvement in overall survival (OS) compared to topotecan, the standard chemotherapy. The trial, conducted in China with 460 patients with recurrent or progressive SCLC, represents the first instance of a B7-H3-targeting ADC demonstrating improved overall survival in a Phase 3 clinical trial for solid tumors. This breakthrough addresses a significant unmet medical need in the SCLC treatment landscape.
The Value of B7-H3 as a Next-Generation Target in the Oncology Market
B7-H3 (CD276) is an immune checkpoint protein that is overexpressed on the surface of various solid tumor cells, including SCLC, contributing to tumor growth and immune evasion, and ultimately worsening patient prognosis. Major pharmaceutical companies are actively pursuing this target due to its high target specificity in cancer cells, making it an ideal candidate for potent ADC platforms. With the positive results from this Phase 3 trial, GSK has gained a significant advantage in the B7-H3 market, where Daiichi Sankyo and MSD are also competing. SCLC has a very low 5-year survival rate of less than 7%, making it a challenging cancer to treat, and the observed improvement in overall survival is likely to expedite the regulatory approval process.
GSK's Proactive Investment in Pipeline Expansion
GSK, previously known for its strengths in vaccines and respiratory therapies, has been actively transforming its business to strengthen its oncology portfolio. In December 2023, GSK entered into an agreement with Hansoh Pharma, paying an upfront payment of $185 million and potential milestone payments of up to $1.525 billion, totaling $1.71 billion, to acquire global rights outside of China. Following the success of this Phase 3 trial, GSK plans to soon submit a Biologics License Application (BLA) to the National Medical Products Administration (NMPA) in China through its partner, Hansoh Pharma. The global Phase 3 trial (ARTEMIS-009, NCT06526624), targeting Western markets, is also expected to gain further momentum.
Fierce Competition in the B7-H3 ADC Market
In the SCLC treatment market, Daiichi Sankyo and MSD's ifinatamab deruxtecan (I-DXd) is currently undergoing Priority Review by the U.S. Food and Drug Administration (FDA), with a PDUFA target action date of October 10, 2026. Amidst this competition, the alliance between GSK and Hansoh Pharma has secured the first Phase 3 data demonstrating improved overall survival, which is expected to have a positive impact on the final review by global regulatory authorities. Furthermore, with Amgen's Imdelltra (tarlatamab), a DLL3-targeted bispecific T-cell engager (BiTE), already approved by the FDA and commercially available, the success of risvutazug rezetecan in the Phase 3 trial is intensifying the competition among multinational pharmaceutical companies for market share in the second-line SCLC treatment market.
The successful ARTEMIS-008 Phase 3 trial represents the first demonstration of survival benefit with a B7-H3-targeted ADC in solid tumors, suggesting a paradigm shift in SCLC treatment and a re-evaluation of the asset's value. GSK's early acquisition of global rights to risvutazug rezetecan through a $1.71 billion deal, including a $185 million upfront payment and $1.525 billion in potential milestones, has enabled the company to rapidly diversify its oncology portfolio. With Daiichi Sankyo's ifinatamab deruxtecan (I-DXd) facing an FDA PDUFA date of October 10, 2026, GSK is aggressively pursuing a leading position in the global SCLC market, which is estimated to be worth approximately $10 billion. From a researcher's perspective, the confirmation of B7-H3's clinical efficacy as a next-generation cancer target will likely accelerate the development of other B7-H3-targeting therapies and the exploration of combination therapies for other solid tumors. In the short term, the submission of a BLA to the Chinese NMPA will likely drive stock performance, while in the medium to long term, the global Phase 3 trial (ARTEMIS-009) is expected to establish GSK as a key player in the U.S. and European markets.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/gsk-hansoh-china-adc-ris-rez-lung-cancer-results/824931/